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Cardiovascular complications associated with diabetes remain a signiﬁcant health issue in westernized societies. Overwhelming
evidence from clinical and laboratory investigations have demonstrated that these cardiovascular complications are initiated by a
dysfunctional vascular endothelium. Indeed, endothelial dysfunction is one of the key events that occur during diabetes, leading
to the acceleration of cardiovascular mortality and morbidity. In a diabetic milieu, endothelial dysfunction occurs as a result of
attenuatedproductionofendothelialderivednitricoxide(EDNO)andaugmentedlevelsofreactiveoxygenspecies(ROS).Thus,in
this review, we discuss novel therapeutic targets that either upregulate EDNO production or increase antioxidant enzyme capacity
in an eﬀort to limit oxidative stress and restore endothelial function. In particular, endogenous signaling molecules that positively
modulate EDNO synthesis and mimetics of endogenous antioxidant enzymes will be highlighted. Consequently, manipulation of
theseuniquetargets,eitheraloneorincombination,mayrepresentanovelstrategytoconfervascularprotection,withtheultimate
goal of improved outcomes for diabetes-associated vascular complications.
1.Introduction
Diabetes mellitus is a highly prevalent chronic metabolic
disorder that is considered a major health problem in west-
ernized societies [1–3]. Diabetes, characterized by persistent
elevation of blood glucose levels (hyperglycaemia), occurs
due to inadequate production of insulin (type 1 diabetes;
T1D), or resistance to endogenous insulin usually associated
with the metabolic syndrome and obesity (type 2 diabetes;
T2D). Despite intensive glycaemic control, individuals with
T1D and T2D are predisposed to developing vascular com-
plications, which include cardiomyopathy, atherosclerosis,
nephropathy, retinopathy, and neuropathy [4, 5]. Indeed,
there is a striking correlation between the incidence of
cardiovasculardiseaseandmortalityratesindiabeticpatients
[6, 7]. Although the mechanisms by which diabetes increases
cardiovascular complications are incompletely understood,
strong supportive evidence from experimental and clinical
studies points to the impaired function of the vascular
endothelium as a critical inducer of these cardiovascular
complications [4, 8]. In the current review, we discuss the
important role of the endothelium and the factors that con-
tribute to diabetes-associated cardiovascular complications,
in particular nitric oxide (NO) bioavailability and reactive
oxygen species (ROS) generation. In addition, this review
will highlight novel compounds or molecules that show
promise in improving vascular function in diabetic settings.
2.The ProtectiveNatureof
the VascularEndothelium
The vascular endothelium, comprised of a single layer of
endothelial cells that line the lumen, was initially only
considered as a physical barrier separating the circulating
blood from the underlying tissue. However, over the past2 International Journal of Vascular Medicine
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Figure 1: Under basal conditions, eNOS is kept in a “less active” state by binding to Cav-1. Activation of eNOS occurs by stimuli, (sheer
stress, agonists such as acetylcholine, Ach), which causes an increase in intracellular Ca2+ and subsequent recruitment of cofactors and
phosphorylation of the enzyme at S1177. Following which, eNOS is dissociated from Cav-1 and eﬃcient EDNO production occurs. CaM:
calmodulin; hsp90: heat shock protein 90.
few decades, the versatile role of the endothelium in cardio-
vascular homeostasis has become more greatly appreciated.
The vascular endothelium is responsible for maintaining
vascular tone and blood pressure which is achieved by
balancing the release of vasoconstrictors and vasodilators
[9]. In addition, the vascular endothelium maintains blood
ﬂuidity by promoting anticoagulant, antiatherosclerotic and
antithrombotic pathways [9]. Endothelial-derived nitric
oxide (EDNO), a potent gaseous mediator released by
endothelial cells, is widely accepted as the key determi-
nant of endothelial function. Importantly, EDNO directly
induces vascular smooth muscle relaxation by the activation
of soluble guanylate cyclase and subsequent increase in
cGMP [10], thereby contributing to resting vascular tone
and blood pressure. EDNO is also considered an anti-
atherogenic and antithrombotic molecule through its ability
to inhibit platelet aggregation, inﬂammatory cell adhesion,
and smooth muscle cell proliferation and migration [11].
Constitutively expressed endothelial nitric oxide synthase
(eNOS) converts L-arginine to nitric oxide using molecular
oxygen in the presence of its cofactors tetrahydrobiopterin
(BH4), heat shock protein 90 (hsp90), and calcium-
calmodulin complex (Figure 1). Additionally, eNOS activity
is signiﬁcantly increased upon phosphorylation at serine
1177, mediated by the protein kinase B/Akt pathway [12].
Importantly, eNOS is only catalytically active upon dissoci-
ation from its endogenous binding protein, caveolin-1 (Cav-
1) [13], which maintains eNOS in a tonic “inhibitory” state
and will be discussed in greater detail below. Indeed, func-
tionalalterationsinEDNOproductionorbioavailabilityplay
a critical role in the pathogenesis of various cardiovascular
diseases [14]. Therefore, regulation and/or improvements in
EDNO bioavailability are a major research focus to delineate
novel drug targets aimed at improving endothelial function
and cardiovascular disease (CVD) outcomes [15].
3.Diabetes-MediatedEndothelialDysfunction
Extensive clinical evidence has demonstrated that diabetic
patients have attenuated EDNO-dependent vascular tone
[16, 17]. The resultant endothelial dysfunction is an impor-
tant precursor of diabetes-mediated vascular events and
has emerged as an independent risk factor for diabetes-
associated cardiovascular complications [18].
Diabetic vessels from murine models and various
endothelial derived cells from vascular beds stimulated with
high glucose, exhibit increased levels of ROS associated
with attenuated EDNO levels [19–21]( Figure 2). It is
now widely accepted that in the diabetic milieu, through
upregulation of the NADPH oxidase (Nox) enzymes [20,
22], ROS such as superoxide are released in pathological
amounts and contribute to the observed reductions in
EDNO bioavailability [23]. In particular, superoxide rapidly
inactivates EDNO forming deleterious peroxynitrite, which
in turn oxidizes the essential eNOS co-factor, BH4, thereby
uncoupling the eNOS enzyme. Consequently, eNOS uncou-
pling diminishes the capacity of the enzyme to produce
EDNO and causes a switch in production to superoxide,
thereby further increasing superoxide levels [20]. The “eNOS
uncoupling” phenomenon has gained an increasing amount
of attention and is considered as one of the major sources
of ROS production. Recently, it has been elucidated that
in a prooxidative environment, eNOS is subjected to S-
glutathionylation, an oxidative post-translational modiﬁca-
tion[24].Thismodiﬁcationoccursspeciﬁcallyatthecysteine
908 residue, thereby aﬀecting the redox function of the
enzyme and leading to an increase in superoxide production
[24, 25]. Furthermore, eNOS S-glutathionylation is associ-
ated with impaired endothelium-dependent relaxation that
is restored by thiol-speciﬁc reducing agents, which reverse
the S-glutathionylation process, in hypertensive vessels [24].
The enhanced superoxide generating activity of the Nox
family of enzymes plays a key role in mediating oxidative
stress and endothelial dysfunction. In the vasculature, the
predominant isoforms of the multisubunit Nox enzyme are
the Nox1, Nox2, and Nox4 isoforms and their regulatory
subunits, including p22phox, p47phox, and Rac-1 [26]. In
streptozotocin- (STZ-) induced murine models and db/db
mice, which represent T1D and T2D respectively, it has been
shown that the expression and activity of these Nox isoforms
and their regulatory subunits are greatly upregulated inInternational Journal of Vascular Medicine 3
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Figure 2: Pathways activated during hyperglycaemia that limit eNOS function and subsequent NO production, leading to endothelial
dysfunction and diabetes-associated vascular disease.
the aortic region and mesenteric vascular bed [22, 27–
29]. Furthermore, this upregulation was associated with
increased oxidative stress and attenuated eNOS expression
and eNOS-derived EDNO [29, 30]. More recently, it was
shown that the increased expression of the Nox catalytic
subunits, in particular Nox2, is directly related to eNOS
uncoupling and eNOS-derived superoxide production in
carotid arteries of diabetic rats [31].
Another cellular signaling pathway that is altered in the
presence of high glucose and contributes to endothelial dys-
functionistheincreaseddenovosynthesisofdiacylglycerides
(DAG) and the subsequent activation of protein kinase C
(PKC) [32, 33]. Indeed, various vascular cells exposed to
hyperglycaemic conditions, as well as tissues from diabetic
animals, have shown a consistent activation of PKC, which in
turn modulates ROS generation and is described extensively
in the review by Yang et al. [33–35]. Finally, recent studies
haveshedlightonthepivotalroleoftheRhoA/Rockpathway
(to be discussed in more detail below), which plays a part in
diabetes-associated endothelial dysfunction via modulation
of eNOS and EDNO levels [21].
Collectively, these studies show that various pathways
are altered in diabetes and that these alterations inﬂuence
the balance between ROS and EDNO production. It is
becoming increasingly clear that this balance between ROS
and EDNO (Figure 2) is critical for vascular health, function
and integrity in diabetes. Therefore, a major research focus
of the past decade has been towards the improvement
of vascular endothelial function via modulation of these
pathways in order to limit or prevent vascular complications
associated with diabetes.
4.ImprovingEndothelial Function:
A ClinicalPerspective
Severaltherapeutic interventions havebeen tested inpatients
with diabetes and cardiovascular disease in an eﬀort to im-
prove endothelial function. These therapeutic interventions,
in particular statin therapy, ACE inhibition, and arginine
supplementation, have shown some improvements in these
disease settings. Statins, which were initially designed as
lipid-lowering drugs, demonstrate lipid-independent eﬀects
such as partially restoring EDNO levels and decreasing
oxidative stress in hypertensive and hypercholesterolaemic
patients [48, 49]. These improvements occurred more
rapidly than the decline in cholesterol levels [48], sug-
gesting that one of the pleiotropic eﬀects of statins is
to enhance endothelial function by upregulating EDNO
signaling. Furthermore, long-term ACE inhibition improved
forearm blood ﬂow, a marker of improved vascular function,
in patients with coronary artery disease and T2D in response
to acetylcholine [50, 51]. Indeed, it was shown that ACE
inhibition attenuated the superoxide-generating eﬀects of
angiotensin II, impaired the breakdown of bradykinin, and
increased the production of EDNO in patients with coronary
artery disease [50]. In addition, L-arginine supplemen-
tation was able to restore diabetes-mediated endothelial-
dependent vasodilation by augmenting cGMP production in
diabetic settings where L-arginine stores were depleted [52].
Although these therapeutic strategies are showing promise
in restoring vascular function in diabetic patients, it is
likely that a more targeted approach focusing speciﬁcally
on the mechanisms that contribute to diabetes-mediated
endothelial dysfunction will ultimately yield more promising
outcomes. This review will now focus on the mechanisms
and novel compounds that speciﬁcally target eNOS signaling
and the regulation of oxidative stress in the context of a
diabetic setting.
5.TargetingeNOS Signalingand
EDNO Production
eNOS is under constant regulation by various factors,
including phosphorylation, transcriptional regulation, direct
interaction with proteins, and substrate and co-factor4 International Journal of Vascular Medicine
Table 1: Novel targets that regulate eNOS function.
Compound Biological action Disease context References
BH4 ↑co-factor availability Endothelium-dependent vasodilation,
hypercholesterolemia, diabetes [36–38]
GTPCH ↑BH4 synthesis Diabetes [39, 40]
AVE9488 ↑eNOS transcription Atherosclerosis, ischemia-reperfusion injury [41, 42]
AVE3085 ↑eNOS transcription Atherosclerosis, hypertension [41, 43]
Fasudil Stabilise eNOS gene expression, ↑eNOS
activity
Atherosclerosis, hypertension, heart failure,
diabetes [44–47]
availability. Furthermore, downstream eﬀectors of various
cellular signaling pathways, such as RhoA, are also capable of
modulating eNOS function. In this section, we highlight the
importance of BH4 availability, transcriptional regulation,
and the role of RhoA and Cav-1 in proper eNOS regulation
and signaling in a diabetic context (see Table 1).
5.1. BH4 Availability. BH4 is a critical co-factor of eNOS
regulation, facilitating electron transfer from its reductase
domaintoitsoxygenasedomain.ForeNOStobecatalytically
active, it must exist in its dimeric form. Indeed, BH4
contributes signiﬁcantly to the stability of the eNOS dimer
[39]. Several reports have indicated that hyperglycaemia
results in signiﬁcant reductions in BH4 levels, thereby
“uncoupling” eNOS to its monomeric form and causing an
increase in eNOS-derived superoxide [39, 40]. Furthermore,
thediabetes-mediatedincreasesinROSlevels,particularper-
oxynitrite,oxidizesBH4 toitsinactiveformdihydrobiopterin
(BH2) [36]. A recent study has shown that BH4 oxidation
is the key determinant for eNOS uncoupling and under
conditions of low BH4 bioavailability, eNOS uncoupling
is suppressed through increased association of eNOS with
Cav-1 [53].
A clinical study has shown that concomitant intra-
arterial infusion of BH4 in type 2 diabetic patients improved
endothelium-dependent vasodilation, demonstrating the
therapeutic potential of upregulating BH4 bioavailabil-
ity [37]. Furthermore, BH4 supplementation improved
endothelial function in vessels from animal models of hyper-
cholesterolaemia and diabetes [36, 38] .T h ei m p o r t a n c eo f
BH4 availability was further strengthened by studies overex-
pressing the rate limiting enzyme guanosine triphosphate-
cyclohydrolase 1 (GTPCH) which is involved in de novo
synthesis of BH4 [39]. Adenoviral-mediated gene transfer of
GTPCH in human endothelial cells exposed to high glucose
conditions rescued eNOS function by increasing EDNO pro-
duction and reducing superoxide levels as well as improving
the stability of the eNOS dimer [39]. These results were
corroboratedinaninvivotransgenicGTPCHoverexpressing
mouse model of T2D, which exhibited markedly improved
EDNO-dependent vascular tone, attenuated oxidative stress,
and increased eNOS dimer to monomer ratio [40]. Thus,
based on preclinical research and limited clinical data,
augmentation of BH4 levels in diabetic patients, appears
to be a feasible strategy to restore impaired endothelial
dysfunction.
5.2. Transcriptional Regulation of eNOS. Various physio-
logical and pathophysiological stimuli are able to modify
the transcriptional activity of the eNOS gene by inducing
transcription or stabilizing steady-state eNOS mRNA levels
[54]. Increased transcription of the enzyme in turn results
in sustained activation of eNOS-dependent activities. For
instance, sheer stress has been implicated in modulating
eNOS mRNA stability while growth factors, such as vascular
endothelial growth factor (VEGF), stimulate transcription
of the eNOS gene [54]. Chemical library screening for
compounds that stimulate eNOS transcription yielded two
small molecular weight compounds, named AVE9488 and
AVE3085, which have demonstrated the ability to increase
EDNO production while concurrently up-regulating eNOS
gene expression and reversal of eNOS uncoupling [41,
43]. In apolipoprotein-E- (ApoE-) deﬁcient mice, AVE9488
and AVE3085 reduced cuﬀ-induced neotima formation
and atherosclerotic plaques, while atherosclerotic plaque
formation was unaﬀected in ApoE/eNOS double knockout
(KO) mice, indicating that the actions of these compounds
are eNOS-speciﬁc [41]. Furthermore, AVE3085 improved
endothelial-dependent vascular function and lowered blood
pressure in spontaneously hypertensive rats [43], and
AVE9488 exhibited cardioprotective eﬀects against ischemia-
reperfusion injury in an EDNO-dependent manner [42].
Although, these transcriptional regulatory compounds have
not been tested directly in a diabetic context, their ability
to ameliorate endothelial dysfunction in pathophysiological
settings, such as hypertension and atherosclerosis, lends
support for their therapeutic potential in diabetes-induced
endothelial dysfunction.
5.3. Potential Role of RhoA. RhoA is a small GTPase protein
involved in several aspects of cellular function including
signal transduction cascades related to vascular inﬂamma-
tion. Amongst its many regulatory functions, activation of
RhoA and its downstream target, Rho-associated kinase
(ROCK), has been shown to downregulate eNOS gene
expression by aﬀecting eNOS mRNA stability and suppress-
ing protein kinase B/Akt activation, thus reducing eNOS
phosphorylation and catalytic activity [12]. Conversely,
administration of the ROCK inhibitor, fasudil, increased
protein kinase B/Akt activity and EDNO release in cultured
endothelial cells [44]. Additionally, fasudil administration
was protective against vascular-injury-induced leukocyte
recruitment in wild type but not eNOS KO mice [44],International Journal of Vascular Medicine 5
conﬁrming that one of the targets of this ROCK inhibitor is
downstream eNOS-dependent activites. Importantly, from a
diabetes perspective, studies have demonstrated a signiﬁcant
correlation between increased RhoA activity and impaired
vascular function in experimental models of T1D and T2D
[21, 55, 56]. Recently, it was shown that increased levels of
ROS, in particular peroxynitrite, suppress eNOS activity in
a RhoA/ROCK-dependent manner in STZ-induced diabetic
rats [12, 21, 55, 56]. Furthermore, treatment with the per-
oxynitritedecompositioncatalyst,FeTTPs,improvedvasore-
laxation to acetylcholine, lowered oxidative-stress and RhoA
activity, upregulated eNOS expression, and improved EDNO
levels [21]. It has also been shown that the RhoA/ROCK
pathway is involved in the pathogenesis of diabetic retinal
microvasculopathy by promoting leukocyte and neutrophil
adhesion to the retinal vasculature, thereby contributing to
endothelial damage [57].
Inhibitors of the RhoA/ROCK pathway are showing
promise as potential regulators of vascular damage. Non-
isoform speciﬁc ROCK inhibitors such as fasudil and Y-
27632 protect against various cardiovascular diseases such
as atherosclerosis, pulmonary and systemic hypertension
and chronic heart failure in clinical and preclinical studies
[45–47]. Mechanistically, Y-27632 has been able to prevent
thrombin-mediated downregulation of eNOS gene expres-
sion in cultured endothelial cells [58]. More importantly,
fasudil has a direct eﬀect on endothelial function, as
demonstrated by improved vascular resistance and forearm
blood ﬂow during intra-arterial infusion of the ROCK
inhibitor [46]. In addition, intravitreal administration of
fasudilsigniﬁcantlyincreasedeNOSactivationanddecreased
leukocyte adhesion in the retinas of diabetic rats [57]. Thus,
the diverse range of beneﬁts associated with inhibiting the
RhoA/ROCK pathway have paved the way for the generation
of newer ROCK inhibitors with higher speciﬁcity between
ROCK isoforms [59]. Currently, only fasudil is approved
for human use in the treatment of acute ischemic stroke
[60]. The testing of fasudil and newer more speciﬁc second
generation ROCK inhibitors in a diabetic setting would be of
great interest in an eﬀort to limit vascular complications.
5.4. Modulating eNOS with Caveolin-1. Cav-1 is the main
structural protein of endothelial cell caveolae, which are
highly dynamic invaginations of the plasma membrane
known to play an integral role in cellular signal transduction
events [14]. Various endothelial cell signaling molecules,
including eNOS, localize in caveolae and are modulated
by direct interaction with Cav-1 [61]. One of the most
intriguingrolesofendothelialCav-1isitsnegativeregulation
of eNOS [61, 62]. Cav-1 has been shown to directly
bind eNOS and to inhibit eNOS-derived EDNO release
under basal conditions (Figure 1)[ 63]. On the contrary,
for optimal EDNO release, eNOS must reside in cave-
olae microdomains. This was clearly demonstrated by a
reduction in EDNO release from HEK 293 cells stably
transfected with palmitoylation-deﬁcient mutants of eNOS,
which lacked the ability of eNOS to target caveolae [64].
Therefore, eNOS is most catalytically active when present
in caveolae microdomains and dissociated from the Cav-
1 protein. Accumulating evidence now suggests that in
cardiovascular disease, endothelial dysfunction occurs as a
result of alterations in the caveolae/Cav-1 signaling pathway
[15]. Supportive evidence for a role for Cav-1 in proper
vascular regulation comes from studies involving Cav-1 KO
animals, which demonstrate dysregulated eNOS synthesis,
increased vascular permeability, cardiomyopathy, and pul-
monary hypertension [65, 66], all of which are rescued upon
reintroduction of Cav-1 back into the endothelium [66, 67].
From the above studies, it is clear that for optimal eNOS
activity, the presence of dissociated eNOS from Cav-1 in
functional caveolae is required. However, both reductions in
C a v - 1a sw e l la so v e r e x p r e s s i o no fC a v - 1h a v eb e e ns h o w n
to aﬀect eNOS activity in diabetic settings. For example, in
a study of moderately diabetic rats, kidney cortical eNOS
dimer-to-monomer ratios and eNOS phosphorylation were
reduced, thereby contributing to the attenuation of proper
EDNO synthesis. Interestingly, eNOS colocalized with Cav-
1 throughout the renal vascular endothelium, however, the
amount of Cav-1 bound to the plasma membrane was
signiﬁcantly attenuated [68]. These data clearly suggest that
the dynamics of membrane bound eNOS/Cav-1 has to be
preserved for proper EDNO synthesis. More recently, it has
been shown that impaired endothelium-dependent vasore-
laxation is linked to increased Cav-1 protein expression in
the aorta of diabetic rats. This was attributed to an inhibition
of eNOS function due to Cav-1 binding and a reduction
in EDNO production [68, 69]. Furthermore, in a diabetic
setting, the interaction of Cav-1 with other pathways has also
been invoked. For example, Cav-1 has been implicated in
diabetic peripheral neuropathy through regulation of neural
cell growth factor receptor Erb 2 signaling [70].
Although a deﬁnite role for Cav-1 in diabetes has
not been fully elucidated, it is apparent that modulating
eNOS function by Cav-1 could be beneﬁcial in ameliorating
diabetes mediated endothelial dysfunction. A major issue
thathaslimitedCav-1researchtodateisthatgeneticablation
of Cav-1 results in the loss of both caveolae and Cav-1
dependent signaling [65]. This makes segregation of the
functional role of caveolae versus Cav-1 dependent signaling
pathways problematic. Hence, a novel approach to target
the eNOS/Cav-1 interaction in a regulated fashion is clearly
warranted. Previous studies have shown that Cav-1 binding
to and inhibition of eNOS is mediated by the putative Cav-
1s c a ﬀolding domain (amino acids 82–101) [61]. By per-
forming alanine scanning of the Cav-1 scaﬀolding domain,
we have determined the amino acids responsible for eNOS
inhibition [63]. Mutation of the amino acids threonine 90,
91 (T90, T91) and in particular phenylalanine 92 (F92) to
an alanine, failed not only to inhibit eNOS activity but also
wasablet oincr easeeNOS-deri v edNOr elease.Thisoc curr ed
despite Cav-1 retaining the ability to bind to eNOS [63, 71].
Moreover, we have generated a cell-permeable Cav-1 peptide
lacking the eNOS inhibitory domain. When this peptide was
applied ex vivo to aortic rings isolated from wild-type mice,
there was an 80% improvement in endothelial-dependent
vasodilation as compared to the wild-type peptide, an eﬀect
that was abolished in eNOS KO mice. This clearly indicates6 International Journal of Vascular Medicine
that eNOS is a speciﬁc target for the mechanism of action
of this peptide. Furthermore, blood pressure was reduced in
vivofollowing an intraperitoneal injection of the peptide in a
concentration dependent manner. Lastly, in endothelial cells,
treatment with the peptide was able to decrease superoxide
production as measured by the cytochrome c assay [71].
Thus, our group has established a more targeted approach
to positively regulate eNOS function by Cav-1. This strategy
has the potential to improve endothelial dysfunction by
upregulating eNOS activity in diabetes and cardiovascular
disease, both of which have impaired Cav-1/eNOS signaling.
However, a limitation that must be taken into account, is
that increasing EDNO levels in the presence of oxidative
stress, could lead to the production of peroxynitrite and
consequently nitrosylation of proteins, leading to further
damage.
6.TargetingOxidantand
AntioxidantPathwaysinDiabetes
The vascular system controls excess ROS through a diverse
range of endogenously expressed antioxidant enzymes, thus
limiting oxidative damage. Antioxidants serve to protect
against oxidative damage by scavenging ROS and interfer-
ing with downstream signaling events mediated by ROS.
However, in diabetes, the activity of vascular ROS-producing
enzymes is increased, whilst antioxidant defences are altered
or impaired, skewing the balance to a more prooxidative
proﬁle. In this section, we discuss a major ROS producing
enzyme of the vasculature and two key vascular antioxidant
enzymes known to play a role in the protection against
endothelial dysfunction and cardiovascular disease induced
by diabetes.
6.1. Nox Isoforms. Since the Nox family of enzymes is one of
the primary sources of ROS in the vasculature, much interest
has focused on ways to minimise ROS production without
compromising the important role played by physiologically
relevant concentrations of ROS [72]. Compounds that
suppressNoxactivitymaythereforeoﬀertherapeuticbeneﬁts
to ameliorate diabetic complications, in particular diabetes
mediated endothelial dysfunction and atherosclerosis where
Nox involvement is increasingly being appreciated [73].
Indeed, it has been suggested that inhibition of vascular
smooth muscle-speciﬁc Nox1 may be an eﬃcient strategy
to suppress neointimal formation in the prevention of
vascular complications associated with diabetes through the
prevention of smooth muscle cell migration, proliferation
and extracellular matrix production [74].
Several novel small-molecule and peptide inhibitors of
the NOX enzymes have been developed and shown to have
promise in experimental studies [75]. Indeed, treatment
with the Nox inhibitor, apocynin, reversed the upregulation
of Nox isoforms, increased eNOS function, and reduced
endothelial dysfunction in STZ-induced and fructose-fed
rats [29, 30]. Apocynin was also eﬀective in improving
vascular function induced by hyperglycaemia in a non-
obese model of T2D [76]. Another novel Nox inhibitor,
VAS2870, lowered superoxide formation in oxidized low-
density-lipoprotein-treated endothelial cells [77]. A highly-
speciﬁcNox inhibitor, known asgp91 ds-tat,hasbeenshown
to interfere with Nox subunit assembly and subsequent
activation of the enzyme. Although gp91 ds-tat has not been
tested in a diabetes-speciﬁc setting, it has shown promise in
a rat model of hypertension through its ability to decrease
vascular ROS and endothelial dysfunction [78, 79].
Even though studies using Nox inhibitors have shown
beneﬁt, the issues of speciﬁcity, potency, and toxicity mil-
itate against any of the existing published compounds as
candidates for drug development. For example, the mode
of action of apocynin has been controversial and a matter
of debate. Recent evidence has suggested that apocynin is
nonselective in its mode of action as it also targets other
enzymes such as Rho-kinase. Indeed, it is now believed to
act as an antioxidant rather than a speciﬁc Nox inhibitor,
as demonstrated in vascular endothelial and smooth muscle
cells [80]. Thus, a more preferable strategy in the design
of Nox-inhibitors would be the development of agents with
isoform and target speciﬁcity. This strategy may be more
beneﬁcial considering the important signaling role provided
by some of the Nox isoforms and the important protective
role of Nox2 in the innate immune response.
6.2.SuperoxideDismutase. Thesuperoxidedismutase(SOD)
enzymes are involved in the removal of superoxide through
its dismutation to oxygen and hydrogen peroxide. The
SOD enzymes are therefore the ﬁrst line of defence against
increases in superoxide and for that reason are impor-
tant regulators of ROS production (Figure 3)[ 81]. Of
relevance to the vasculature, the SOD enzymes are also
a key determinant of EDNO bioavailability since SOD
competes with EDNO for superoxide in a diﬀusion-limited
manner, thus attenuating the formation of peroxynitrite.
In doing so, the SOD enzymes indirectly improve EDNO
bioavailability[82].Indeed,inmicewithageneticablationof
the cytosolic Cu/Zn-containing isoform, SOD1, endothelial
dysfunction was associated with increased superoxide and
peroxynitrite levels compared with wild type controls [83].
Furthermore, exogenously added SOD was able to partially
restore endothelium-dependent vasodilation in an eNOS-
dependent manner in SOD1 KO mice [83]. In addition,
overexpressing the mitochondrial isoform, SOD2, specif-
ically in the endothelium of STZ-induced diabetic mice,
prevented diabetic retinopathy and superoxide-mediated
oxidative stress [84]. These data clearly demonstrate the
important role SOD plays in balancing oxidative stress
through removal of superoxide and thereby maintaining
EDNO levels.
Studies assessing the level of antioxidant defence in
diabetes are mostly in agreement that antioxidant capacity
is compromised in the diabetic milieu. Indeed, lower SOD1
activity has been associated with both T1D and T2D patients
[85–87] and with increased susceptibility to vascular disease
in children with T1D [88]. However, paradoxically in one
study of a rabbit model of diabetes, impaired vascular func-
tion was linked to increased SOD expression and augmented
superoxide levels [89]. However, adenoviral ex vivo geneInternational Journal of Vascular Medicine 7
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transfer of both SOD1 and SOD2 into these diabetic rabbits
improved vascular function by decreasing superoxide levels,
leading these authors to conclude that, despite the increase
in endogenous SOD, it had been rendered functionally
less active and therefore unable to cope with the elevated
diabetes-mediated oxidative stress [89]. This was conﬁrmed
in human endothelial cells, where exposure to high glucose
for 7 and 14 days increased SOD1 and SOD2 protein levels
despite SOD activity declining, therefore stressing the need
for functionally active SOD to protect against oxidative stress
[90].
Cardiovascular clinical trials investigating the potential
of exogenous antioxidants, such as vitamin C and E, to
bolster antioxidant defences have failed to show a positive
outcome with respect to CVD endpoints [91, 92]. This lack
of improvement in cardiovascular outcomes has spawned
the development of compounds that mimic endogenous
antioxidant enzymes with greater cellular penetration, eﬃ-
cacy, and stability, in order to lower oxidative stress in
disease settings. Indeed, administration of tempol, a cell-
permeable SOD mimetic, has shown improvements in
diabetes associated microvascular complications, such as
nephropathy and retinopathy [93, 94]. In addition, tempol
restored endothelial vasorelaxation in large conduit vessels
of alloxan-induced diabetic rabbits [95]. MN40403, another
highly speciﬁc nonpeptide SOD mimetic was able to reverse
endothelial dysfunction ex vivo by targeting Nox-mediated
superoxide production in aortae of ApoE-deﬁcient mice
[96].
Lastly, it is important to note that although SOD and
SOD mimetics have displayed eﬃcacy in experimental mod-
elsofdiabetes,theirroleinimprovingdiabetic vascularcom-
plications remains controversial. This may be due to the fact
that in pathological conditions, dismutation of superoxide
by SOD is linked to excess production of hydrogen peroxide,
anotherROSknowntocauseirreversibleendothelialdamage
and attenuate EDNO production [97]. Thus, the availability
orconcurrentadditionofotherantioxidantssuchascatalase,
thioredoxins, peroxiredoxins, and glutathione peroxidases,
which function to neutralize hydrogen peroxide and/or
hydroxyl radicals, may prove to be a more eﬀective therapy
to combat oxidative stress [81].
6.3. GPx1: A Versatile Antioxidant Enzyme. Glutathione per-
oxidases (GPx) are a family of selenocysteine-containing
enzymesthatparticipateinthesecondstepoftheantioxidant
pathway, which involves the neutralization of hydrogen
peroxide to water (Figure 3) utilizing glutathione (GSH) as
its substrate [81, 98]. GPx1 is the predominant isoform
expressedinthecytosolandmitochondria.Underconditions
ofincreasedoxidativestress,abuild-upofhydrogenperoxide
favours the production of hydroxyl radicals through Fenton-
type reactions, leading to the formation of lipid peroxides.
The formation of lipid peroxides in turn damage cell mem-
branes and contribute to the pathogenesis of atherosclerosis
[99]. GPx1 is considered a multifaceted antioxidant enzyme
in its ability to eliminate lipid peroxides, hydrogen peroxide
[81] and reduce the potent peroxynitrite anion [81, 100]
(Figure 3). Indeed, recent preclinical and clinical data have
shown that GPx1 plays a critical role in protecting the car-
diovascular system against oxidative stress [101, 102]w i t h
low levels of GPx1 activity acknowledged as an independent
riskfactorforcardiovasculareventsinpatientswithcoronary
artery disease [102].
The generation of GPx1 KO mice by our group [103]a n d
others [104, 105] have speciﬁcally demonstrated the impor-
tance of GPx1 in protecting the vasculature against oxidative8 International Journal of Vascular Medicine
stressandvascularcomplicationsofdiabetes[106].Although
deletion of GPx1 is nonlethal and GPx1 KO mice are fertile
[81, 103], these mice have an enhanced oxidative stress
proﬁle and are more susceptible to endothelial dysfunction
[107, 108]. Indeed, a 50% reduction of GPx1, as seen in
heterozygous mice, is suﬃcient to impair endothelial func-
tion and cause signiﬁcant abnormalities to the vasculature
and cardiac structures [101, 108]. Furthermore, resistance
arteries isolated from GPx1 KO mice displayed paradoxi-
cal vasoconstriction in response to bradykinin, a EDNO-
dependent vasodilator, whilst their wild-type counterparts
exhibited dose-dependent vasodilation [107]. These ﬁndings
were accompanied by reduced levels of cGMP, a downstream
signaling molecule of the EDNO pathway, with no change in
eNOS expression within the aorta of GPx1 KO mice [107].
These ﬁndings are strongly suggestive that a deﬁciency in
GPx1 contributes to the reduction in EDNO bioavailability.
In support of this ﬁnding, Galasso et al. demonstrated
impaired ischemia-induced angiogenesis, as well as a reduc-
tioninthenumberofendothelialprogenitorcellsinresponse
to vascular endothelial growth factor stimulation in GPx1
KO mice, both processes known to be EDNO dependent
[109]. In addition, GPx1 deﬁciency has been shown to
accelerate angiotensin-II-mediated endothelial dysfunction,
cardiac hypertrophy, and mean arterial blood pressure [110,
111].
Armed with this knowledge, our group was particularly
interested in the role of Gpx1 in vascular complications
associated with diabetes. In order to achieve these aims,
we generated ApoE/GPx1 double KO (dKO) mice and
rendered them diabetic using STZ, which proved to be
a robust model for diabetes-associated atherosclerosis and
nephropathy [106, 112]. In diabetic ApoE/GPx1 dKO mice,
atherosclerotic lesions were signiﬁcantly increased in all
regions of the aorta and aortic sinuses compared with
diabetic ApoE KO mice. The enhanced atherosclerosis was
accompanied by an increase in proatherogenic inﬂammatory
markers, such as VCAM-1 and Nox2, and the pro-ﬁbrotic
markers, CTGF and VEGF [106]. In the absence of GPx1,
there was an upregulation in SOD 1 and catalase, however,
this compensatory response was insuﬃcient to protect the
mice against oxidative stress-mediated damage, as quantiﬁed
by the increased nitrotyrosine levels detected in ApoE/GPx1
dKO compared with ApoE KO counterparts [106]. Diabetic
nephropathy, detected as increased albuminuria, creatinine
clearance,mesangialexpansion,oxidativestress,andﬁbrosis,
was also signiﬁcantly enhanced in diabetic ApoE/GPx1 dKO
mice compared with diabetic ApoE KO controls [112].
Collectively, these studies implicate a major role for GPx1 in
protecting the vasculature against hyperglycaemia-mediated
oxidative stress, endothelial dysfunction, atherogenesis, and
nephropathy.
Ebselen is a lipid-soluble seleno-organic compound,
which mimics the activity of GPx1. Clinical studies have
demonstrated that ebselen has neuroprotective eﬀects in
stroke patients, showing its suitability and safety for human
usage. In addition, Ebselen has been extensively studied for
its therapeutic potential in various experimental models of
diabetes [112–115]. In a T2D rat model associated with
metabolic syndrome, a reduction in endothelium-dependent
vasodilation as well as EDNO production and angiogenic
capacity was prevented by treatment with ebselen [115].
Additionally, we have shown that ebselen is protective
against atherosclerosis in diabetic ApoE KO mice, which was
associated with a decrease in oxidative stress markers and
reduced expression of proatherogenic cellularity and medi-
ators [113]. In endothelial cells, pretreatment with ebselen,
diminished hydrogen-peroxide induced increases in inﬂam-
matory cytokines, such as TNF-α and NFkB, and attenuated
the TNF-α-induced expression of endothelial cell adhesion
molecules (VCAM-1 and ICAM-1) [113, 116]. Importantly,
in our studies, ebselen was able to signiﬁcantly improve
diabetes-associated atherosclerosis and nephropathy in our
ApoE/GPx1 dKO mice [112]. This ﬁnding was pivotal as
it demonstrated that ebselen, a synthetic compound that
mimics an endogenous antioxidant enzyme, is target speciﬁc
and able to lessen the pathological consequences brought
about by a deﬁciency in GPx1.
Currently, newer ebselen analogues with structural mod-
iﬁcations,including adiselenide moiety,havebeengenerated
for their greater eﬃcacy, potency, and their potential to
behave in a superior fashion to ebselen in vivo. Indeed,
thorough biochemical and kinetic analysis have proven that
these analogues have a higher catalytic activity [117]. Most
recently, Hort et al. have shown that daily treatment of
hypercholesterolemic LDL receptor KO mice with diphenyl
diselenide (0.1mg/kg or 1mg/kg) for 30 days, reduced
atherosclerotic lesions, which was accompanied by improved
vascular function, downregulation of proatherogenic genes,
reduced inﬁltration of inﬂammatory cells, and lowered
oxidative stress levels [118]. These ﬁndings are supported
by our own unpublished observations with various other
ebselen analogues designed for their improved activity,
which have demonstrated their antiatherogenic potential
in diabetic ApoE/GPx1 dKO mice. Accordingly, targeting
GPx1 activity through the use of novel GPx1 mimetics is
proving beneﬁcial in various preclinical settings, provid-
ing a strong foundation for their translation into clinical
trials.
7. Conclusion
It is now well accepted that proper regulation of endothelial
function in diabetes is considerably impaired, leading to
often fatal cardiovascular complications. EDNO bioavail-
ability and oxidative stress are two separate but inter-
linked determinants of vascular function that are both
compromised in a diabetic setting. Hence, developing novel
therapeutics to speciﬁcally improve EDNO bioavailability
and reduce oxidative stress is a clearly desirable dual
strategy to manage endothelial dysfunction. This review
highlights the importance of developing new compounds
that upregulate EDNO synthesis, target key vascular ROS-
producing enzymes, and mimic endogenous antioxidants, a
strategy that might prove clinically relevant in preventing
thedevelopmentand/orretardingtheprogressionofdiabetes
associated vascular complications.International Journal of Vascular Medicine 9
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